Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity PharmAust Limited ABN 35 094 006 023 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Mr Robert Charles Bishop Date of last notice 18 December 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) The securities are held by Longbow Croft Capital Pty Ltd and First Capital Markets Pty Limited. Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change Class Number acquired Number disposed Mr Bishop is the sole shareholder and director of Longbow Croft Capital Pty Ltd and First Capital Markets Pty Limited. 2 January 2024 9,511,060 Ordinary Fully Paid Shares 150,000 Unlisted Options 30/04/26 – 15c 2,302,766 Listed Options 30/04/2026 – 15c Unlisted Options 30/04/26 – 15c Listed Options 30/04/2026 – 15c 150,000 150,000 Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back + See chapter 19 for defined terms. 01/01/2011 9,511,060 Ordinary Fully Paid Shares 2,452,766 Listed Options 30/04/2026 – 15c As per Appendix 2A lodged on 2 January 2024 and under the Prospectus dated 21 November 2023, the Company sought quotation of the existing 15 cent unlisted Options as they have the same exercise price and expiry date and general terms Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided? No + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity PharmAust Limited ABN 35 094 006 023 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Mr Sam Michael Wright Date of last notice 18 December 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) The securities are held by Straight Lines Consultancy Pty Ltd as trustee for the Straight Lines Trust. Mr Wright is a Director of Straight Lines Consultancy Pty Ltd and a Beneficiary of the Straight Lines Trust. Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change Class Number acquired Number disposed 2 January 2024 4,550,000 Ordinary Fully Paid Shares 250,000 Unlisted Options 30/04/26 – 15c 875,000 Listed Options 30/04/2026 – 15c Unlisted Options 30/04/26 – 15c Listed Options 30/04/2026 – 15c 250,000 250,000 Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back 4,550,000 Ordinary Fully Paid Shares 1,125,000 Listed Options 30/04/2026 – 15c As per Appendix 2A lodged on 2 January 2024 and under the Prospectus dated 21 November 2023, the Company sought quotation of the existing 15 cent unlisted Options as they have the same exercise price and expiry date and general terms + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided? No + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity PharmAust Limited ABN 35 094 006 023 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Mr Neville John Bassett AM Date of last notice 18 December 2023 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) Shares are held by Mandevilla Pty Ltd. Mr Bassett is a director and shareholder of Mandevilla Pty Ltd. Note: Provide details of the circumstances giving rise to the relevant interest. Date of change No. of securities held prior to change Class Number acquired Number disposed 2 January 2024 507,000 Ordinary Fully Paid Shares 250,000 Unlisted Options 30/04/26 – 15c 1,750 Listed Options 30/04/2026 – 15c Unlisted Options 30/04/26 – 15c Listed Options 30/04/2026 – 15c 250,000 250,000 Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back 507,000 Ordinary Fully Paid Shares 251,750 Listed Options 30/04/2026 – 15c As per Appendix 2A lodged on 2 January 2024 and under the Prospectus dated 21 November 2023, the Company sought quotation of the existing 15 cent unlisted Options as they have the same exercise price and expiry date and general terms + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided, on what date was this provided? No + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011